Novartis Ag (NVS)
$85.91 0.80 (0.92%)
19:40 EST NVS Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 200.24B
PE Ratio 25.19
Volume (Avg. Vol.) 2.23M
Day's Range 85.63 - 87.21
52-Week Range 69.18 - 98.52
Dividend & Yield 2.98 (3.47%)
NVS Stock Predictions, Articles, and Novartis Ag News
- From InvestorPlace
- From the Web
By Alex Sirois
Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.
Although it’s one of the major pharmaceuticals, Novartis didn’t directly jump into the vaccine race. That might have been the best move for Novartis stock.
Alexandria Real Estate Equities is the largest landlord in the US for laboratories and related offices.
As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.
There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.
The sector is a safe bet for long-term growth, but which health-care stocks stand to gain the most? Here are three picks to consider today.
Tesla hit 200,000 pre-orders and there was a bevy of M&A to report. Here's what happened in the stock market today.
The Medicines Company (MDCO) news for Monday about a $9.70 billion deal with Novartis (NVS) has MDCO stock heading higher.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
With FDA Breakthrough Therapy designations and robust drug pipelines, these biotech companies are all stocks to buy for 2020.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Ford, Verizon and AbbVie are just a trio of the top dividend stocks to buy for the remainder of 2019, particularly if the broad market hits turbulence.
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.
Following a long, steep correction and on the heels of earnings, there’s less to fear in stepping into a contrarian position in Tilray stock.
Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors. Here are 3 that stand to benefit from the rise of legal cannabis use.
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader